Antibacterial synergist 3
Antibacterial synergist 3 is a dual-acting inhibitor of biofilm (IC50 of PAO1: 0.40 μM and IC50 of PA14: 1.45 μM). Antibacterial synergist 3 reduces virulence production by inhibiting the quorum sensing (QS) system and induces iron deficiency in P. aeruginosa PAO1. Antibacterial synergist 3 enhances the efficacy of Tobramycin (HY-B0441) and Ciprofloxacin (HY-B0356) in a mouse wound infection model. Antibacterial synergist 3 can be used for the research of P. aeruginosa infections.
For research use only. We do not sell to patients.
- Formula: C15H20N4O4S
- Molecular Weight:352.41
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
Antibacterial synergist 3 (compound JH21) (0.15625-2.5 μM) reduces the biofilm formation rate of P. aeruginosa PAO1 in a concentration-dependent manner[1].
Antibacterial synergist 3 (0.3125-10 μM) reduces the production of P. aeruginosa virulence factors elastase (43%) and pyocyanin (42%), and decreases the production of biofilm matrix exopolysaccharides (58%)[1].
Antibacterial synergist 3 (0.3125-10 μM) suppresses the fluorescence of PAO1-lasB-gfp and PAO1-pqsA-gfp strains but has no effect on the fluorescence of PAO1-gfp and its growth, indicating that it inhibits both the las and pqs systems[1].
Antibacterial synergist 3 (0.3125-10 μM) reduces the iron content of P. aeruginosa PAO1 (57%)[1].
Antibacterial synergist 3 (0.3125-10 μM) inhibits the swarming (84%) and swimming (64%) motility of P. aeruginosa PAO1 in a concentration-dependent manner[1].
Antibacterial synergist 3 (1.25-40 μM) shows no significant hemolytic effect on mouse and rabbit erythrocytes, indicating that it has good biosafety[1].
Antibacterial synergist 3 (1.25-100 μM) shows no cytotoxicity to RAW264.7 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Antibacterial synergist 3 (2.5 μM, topical, 3 d) combined with Ciprofloxacin (HY-B0356) (0.001 mg/mL) can reduce the survival rate of P. aeruginosa in the mouse wound infection model (0.45%) and significantly increase the antibacterial effect of Ciprofloxacin (HY-B0356) (1000 times)[1].
Antibacterial synergist 3 (0-100 μM, 0-120 h) does not affect the survival rate of zebrafish larvae (100%) in the zebrafish model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mouse wound infection model, female mice (4-week-old, babl/c) were infected with PAO1 (5 × 108 CFU in 0.9% saline)[1]
-
Dosage:2.5 μM
-
Administration:Topical, 3 d
-
Result:Compared with the use of 0.5 mg/mL Tobramycin alone, the antibacterial rate (0.97%/0.22%) and wound healing rate (35%/36%) were equivalent, and the efficacy was improved by 200 times.
Compared with the use of 1 mg/mL Ciprofloxacin alone, the antibacterial rate (0.45%/0%) and wound healing rate (38%/39%) were equivalent, and the efficacy was improved by 1000 times.
Chemical Information
-
Molecular Weight 352.41
-
Formula C15H20N4O4S
-
SMILES
ONC(CCCCNC(CNC1=NC2=CC=C(C=C2S1)OC)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Antibacterial synergist 3 Related Classifications
HY-173270 Related Classifications
Powered by Bioz